EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

Weimin Qiu iD, Hui Liu, Yijun Liu, Xin Lu, Lei Wang, Yanyu Hu, Feng Feng, Qi Li, Haopeng Sun iD

Medicinal Research Reviews · 2023

DOI: 10.1002/med.21947 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2023. Verfasst von Weimin Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 228 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is difficult to treat. Extracellular amyloid is the principal pathological criterion for the diagnosis of AD. Amyloid β (Aβ) interacts with various receptor molecules on the plasma membrane and mediates a series of signaling pathways that play a vital role in the occurrence and development of AD. Research on receptors that interact with Aβ is currently ongoing. Overall, there are no effective medications to treat AD. In this review, we first discuss the importance of Aβ in the pathogenesis of AD, then summarize the latest progress of Aβ‐related targets and compounds. Finally, we put forward the challenges and opportunities in the development of effective AD therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeurodegenerative DiseasesHumansAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein Secretases

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid β receptoramyloid β secretaseamyloid β transporter

Substanzen

Amyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein Secretases

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
  • Department of Natural Medicinal Chemistry, Jiangsu Food and Pharmaceuticals Science College, Institute of Food and Pharmaceuticals Research, Jiangsu, Huaian, China.
  • Department of Pharmacology, School of Basic Medicine, Qingdao University, Qingdao, China.

ORCID-Profile: Weimin Qiu, Haopeng Sun

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Qiu, W., Liu, H., Liu, Y., Lu, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023). Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds. Medicinal Research Reviews. https://doi.org/10.1002/med.21947

Vancouver

Qiu W, Liu H, Liu Y, Lu X, Wang L, Hu Y, et al. Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds. Medicinal Research Reviews. 2023. doi:10.1002/med.21947

BibTeX
@article{Qiu2023,
  author = {Qiu, Weimin and Liu, Hui and Liu, Yijun and Lu, Xin and Wang, Lei and Hu, Yanyu and Feng, Feng and Li, Qi and Sun, Haopeng},
  title = {Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds},
  journal = {Medicinal Research Reviews},
  year = {2023},
  doi = {10.1002/med.21947}
}
Kostenlos starten →